Sugi Predict

Sugi Predict / Compounds / SCHEMBL729028

SCHEMBL729028

SCHEMBL729028

O=C(CCN1C(=O)c2ccccc2C1=O)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.60
▸ HSD17B10 Q99714 3/20 0.60
▸ ALOX15 P16050 1/20 0.60
▸ TSHR P16473 1/20 0.60
▸ SMN1; SMN2 Q16637 4/20 0.59
▸ POLB P06746 1/20 0.56
▸ CA12 O43570 1/20 0.55
▸ CA9 Q16790 1/20 0.55
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ KMT2A Q03164 4/20 0.54
▸ HPGD P15428 2/20 0.54
▸ GAA P10253 1/20 0.54
▸ GSK3B P49841 1/20 0.53
▸ MAPT P10636 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8562369 0.90 SMN1; SMN2 (0.56) ALDH1A1HSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL17267467 0.88 HDAC8 (0.61) ALDH1A1HSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL3025973 0.87 GSK3B (0.72) ALDH1A1HSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL7345361 0.87 SMN1; SMN2 (0.63) ALDH1A1HSD17B10SMN1; SMN2POLBCA12
SCHEMBL4569136 0.84 POLB (0.53) ALDH1A1HSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL30098360 0.83 CA12 (0.66) ALDH1A1HSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL135305 0.83 CA12 (0.66) ALDH1A1HSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL17735453 0.83 CYP1A2 (0.59) ALDH1A1HSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL2754744 0.83 ALDH1A1 (0.48) ALDH1A1HSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL3188858 0.82 KMT2A (0.55) ALDH1A1HSD17B10ALOX15TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200060997-A1 TARR Receptor Agonists for Sexual Dysfunction JOHN MCCOY 2020-02-27 — — US claimed
US-20160000815-A1 COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS GOSFORTH CT HOLDINGS PTY LTD (AU) 2016-01-07 — — US claimed
US-20140142140-A1 PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) 2014-05-22 — — US claimed
EP-2729216-A1 PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS Gosforth Centre (Holdings) Pty Ltd (AU) 2014-05-14 — — EP claimed
WO-2013007698-A1 PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) 2013-01-17 — — WO claimed
JP-2011529923-A — — 2011-12-15 — — JP claimed
US-20110207718-A1 COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) 2011-08-25 — — US claimed
EP-2331088-A1 COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS Gosforth Centre (Holdings) Pty Ltd (AU) 2011-06-15 — — EP claimed
WO-2010015029-A1 COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) 2010-02-11 — — WO claimed
WO-2026106796-A1 SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS FOLLEA INTERNATIONAL (US) 2026-05-21 — — WO disclosed
US-20260041652-A1 SYSTEM AND METHOD FOR PREVENTING ALOPECIA FOLLEA INT (US) 2026-02-12 — — US disclosed
CN-118184477-A Method for preparing chiral amino alcohol compound by catalyzing amino ketone with nickel metal by using water as hydrogen source 云南民族大学 2024-06-14 — — CN disclosed
WO-2024118094-A1 SYSTEM AND METHOD FOR PREVENTING ALOPECIA FOLLEA INTERNATIONAL (US) 2024-06-06 — — WO disclosed
WO-2024107708-A1 TAAR RECEPTOR AGONISTS FOR SEXUAL DYSFUNCTION ReJoy (US) 2024-05-23 — — WO disclosed
US-20070185106-A1 Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists ASTRAZENECA AB (SE) 2007-08-09 — — US disclosed
US-20070167428-A1 Thienopyrroles as antagonists of gnrh ASTRAZENECA AB (SE) 2007-07-19 — — US disclosed
US-20050148581-A1 Novel mycobacterial inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2005-07-07 — — US disclosed
EP-1527050-A1 QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-05-04 — — EP disclosed
WO-2004011436-A1 QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2004-02-05 — — WO disclosed
US-3971772-A ANTINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1976-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185106-A1 Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists GNRHR, PRLHR, GHRHR ALDH1A1 4371/4885HSD17B10 2544/4885ALOX15 4352/4885
US-20050148581-A1 Novel mycobacterial inhibitors NDUFB5, MT-ND1, NDUFB7 ALDH1A1 2415/4885HSD17B10 2043/4885ALOX15 3276/4885
US-20070167428-A1 Thienopyrroles as antagonists of gnrh GNRHR, PRLHR, TRHR ALDH1A1 3935/4885HSD17B10 2719/4885ALOX15 3931/4885
US-20260041652-A1 SYSTEM AND METHOD FOR PREVENTING ALOPECIA DYRK4, DYRK2, STRA6 ALDH1A1 4003/4885HSD17B10 3412/4885ALOX15 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.